AGIO: Financial results

Item 2.02 Results of Operations and Financial Condition. On July 30, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2026 and other business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued July 30 , 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AGIOS PHARMACEUTICALS, INC. Date: July 30, 2026 By: /s/ Brian Goff Brian Goff Chief Executive Officer